

Pfizer Inc.
 275 North Field Drive
 Lake Forest, IL 60045

February 20, 2017

BICILLIN® L-A (penicillin G benzathine injectable suspension)
BICILLIN® C-R (penicillin G benzathine and penicillin G procaine injectable suspension)
PENICILLIN G PROCAINE (penicillin G procaine injectable suspension)

SUPPLY UPDATE

Dear Customer,

Pfizer Injectables is committed to providing information on supply so that appropriate plans can be made to facilitate patient care and safety. We want to provide updated information on the supply status of the prefilled syringes containing Penicillin.

BICILLIN L-A

Pfizer remains on track for the next anticipated deliveries and continues to allocate product to the market weekly as outlined in the table. As previously communicated, Pfizer expects a supply improvement by late March, which should allow allocations to the market to be increased and we plan to keep this allocation in place until complete recovery in 4Q 2017. We continue to recommend consideration of prioritizing where BICILLIN L-A is the only choice for the patient's treatment. Please consider alternative drugs where clinically applicable.

Unit of Sale NDC	Presentation	Allocation % range (of normal demand)	Anticipated Next Delivery
60793-700-10	Pediatric 600,000 Units/1 mL PFS*	30%-40%	Feb-17
60793-701-10	1,200,000 Units/2 mL PFS*	45%-55%	Mar-17
60793-702-10	2,400,000 Units/4 mL PFS*	48%-58%	Mar-17

*Prefilled Syringe

Trading partners placed BICILLIN L-A on allocation to help as many customers as possible have access to supply until the next anticipated product shipments arrive. Note that the allocation percent range may change. Please work with your trading partner on obtaining the product.

BICILLIN C-R

Pfizer received the expected deliveries for January and has resumed allocating product to the market as outlined in the table below. Pfizer expects to continue to allocate product at 90% of normal demand until complete recovery is in place for all presentations which is estimated as 4Q 2017. The updates are noted in red.

BICILLIN C-R:

Unit of Sale NDC	Presentation	Allocation % range (of normal demand)	Anticipated Next Delivery
60793-600-10	1,200,000 Units/2 mL PFS*	90%	July-17
60793-601-10	Pediatric 1,200,000 Units/2 mL PFS*	90%	July-17
60793-602-10	900/300 Pediatric 1,200,000 Units/2 mL PFS*	Not available**	Feb-17

*Prefilled Syringe

** Upon receipt in February, we plan to allocate at 90% of normal demand

PENICILLIN G PROCAINE

This product is currently on backorder and there is no change at this time to the product availability. The next anticipated delivery is April 2017 for both presentations:

Unit of Sale NDC	Presentation	Supply Status	Anticipated Next Delivery
60793-130-10	600,000 Units/1 mL PFS*	Not available	Apr-17
60793-131-10	1,200,000 Units/2 mL PFS*	Not available	Apr-17

*Prefilled Syringe

We are working closely with the FDA on the shortage of these critical drugs. This information is also being provided to the Centers for Disease Control and Prevention, American Society of Health-System Pharmacists (ASHP), and to the Group Purchasing Organizations.

Please check the FDA and ASHP Drug Shortage websites for future updates.

For full Prescribing Information including BOXED WARNING, please visit www.pfizerinjectables.com.

Regards,
Shawn Olsson
Pfizer Injectables